ISU302
Phase 3Small molecule
ISU302 is one of 23 small molecule programs targeting Gaucher Disease. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Gaucher Disease
#DrugCompanyPhaseTrials
1Busulfex
Akero TherapeuticsApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Opfolda
Johnson & JohnsonPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
ELELYSO
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cerdelga
GGenzyme, a Sanofi Company
Phase 3
Cerezyme
SanofiApproved
CEREZYME
GGenzyme, a Sanofi Company
Phase 3
Gene Therapy
CCapsida Biotherapeutics, Inc.
Phase 3
Elelyso
SShaare Zedek Medical Center
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ISU302. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IISU Abxis Co., Ltd.